Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

GEHC · Q1 2026 Earnings

GE HealthCare

Reported April 29, 2026

30-second summary

30-second take. GE HealthCare delivered Q1 FY2026 revenue of $5.13B (+7.4% YoY reported, +2.9% organic — at the high end of the 2-3% guide) and non-GAAP EPS of $0.99, but the story is a material guidance cut driven by ~$250M of incremental memory chip, freight, and commodity inflation. FY2026 adjusted EPS was lowered to $4.80-$5.00 from $4.95-$5.15 (midpoint -$0.15), EBIT margin to 15.4-15.7% from 15.8-16.1% (-40bps across the range), and FCF to ~$1.6B from ~$1.7B, while organic growth was held at 3-4% — implying the back half must accelerate. Q2 FY2026 EPS is guided to a low-single-digit YoY decline, the first explicit signal of in-quarter EPS pressure since the tariff shock a year ago.

Headline numbers

EPS

Q1 FY2026

$0.99

Revenue

Q1 FY2026

$5.13B

+7.4% YoY

Gross margin

Q1 FY2026

38.5%

Free cash flow

Q1 FY2026

$0.11B

Operating margin

Q1 FY2026

10.0%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$5.13B	+7.4%	$5.70B	-10.0%
EPS	$0.99	—	$1.44	-31.3%
Gross margin	38.5%	—	39.7%	-120bps
Operating margin	10.0%	—	14.5%	-450bps
Free cash flow	$0.11B	—	$0.92B	-87.8%

Guidance

Guidance materially cut: FY2026 EPS and margin guidance lowered, full-year growth outlook reduced from 7.9–12.3% to 4.6–9.0% YoY; Q2 expected to see EPS decline YoY.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Organic revenue growth (YoY)	Q1 FY2026	2% to 3%	2.9%	at high end of guide	Beat
Adjusted EPS growth (YoY)	Q1 FY2026	mid-single-digit	0.99	below mid-single-digit growth implied by guidance	Missed

New guidance

Metric	Period	Guide	YoY
Organic revenue growth (YoY)	Q2 FY2026	3% to 4%	-0.4% to 9.6%
Adjusted EPS (YoY)	Q2 FY2026	decline in the low single digits	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY2026	$4.95 to $5.15	$4.80 to $5.00	-$0.15 (low end); -$0.15 (high end)	Lowered
Adjusted EPS growth (YoY)	FY2026	7.9% to 12.3%	4.6% to 9.0%	-3.3pts (low); -3.3pts (high)	Lowered
Adjusted EBIT margin	FY2026	15.8% to 16.1%	15.4% to 15.7%	-0.40pts (low); -0.40pts (high)	Lowered
Free cash flow	FY2026	approximately $1.7 billion	approximately $1.6 billion	-$0.1 billion	Lowered

Reaffirmed unchanged this quarter: Adjusted ETR (20.0% to 21.0%), Organic revenue growth (YoY) (3.0% to 4.0%)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Imaging	$2.299B	+3.8%
Advanced Visualization Solutions	$1.341B	+4.4%
Patient Care Solutions	$0.704B	-8.1%
Pharmaceutical Diagnostics	$0.77B	+9.7%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Organic Revenue Growth	2.9%
Adjusted EBIT Margin	13.5%
Book-to-Bill Ratio	1.07x
Backlog	$21.8B
Organic Orders Growth	1.1%
Net Income Margin	7.6%
Free Cash Flow	$112M
Operating Cash Flow	$290M

Management tone

Q1 anchor (tariff shock + raised FY) → Q2 anchor (tariff mitigation, H2 cycle teed up) → Q3 anchor (2026 acceleration framing) → Q4 anchor (Heartbeat margin expansion) → Q1 FY2026 anchor (defensive guidance cut on inflation shock).

Three quarters ago tariffs were the dominant cost variable and management was positioning the supply-chain restructuring as a "no regrets" structural win; two quarters ago the framing pivoted to Heartbeat productivity driving 50-80bps of independent margin expansion; this quarter the same management team is reducing FY profit and free cash flow guidance and explicitly using the word "prudent." From the release: "taking a prudent view and reducing our profit and free cash flow guidance for 2026." The shift signals that the structural margin claim the bull case rested on last quarter is now contingent on inflation easing, not on Heartbeat alone.

The H2 acceleration thesis has been pushed out by another six months. On the Q3 FY2025 call Arduini said the nine major launches would "impact performance on sales in the second half of the year" with bigger 2027 impact; on the Q4 call Saccaro tightened this to "second half of 2026." This quarter the language is "we expect revenue contribution from our key imaging NPIs to begin in the first half of 2027." The launches themselves are not delayed — regulatory clearances and early commercial orders are progressing — but the revenue conversion timeline has slipped roughly two quarters in two prints. This matters because the FY2026 organic guide of 3-4% (held flat) implicitly assumes back-half acceleration that the imaging NPI pipeline can no longer fully underwrite.

PCS reframed from "mechanical recovery in hand" to "candidate for strategic assessment" in one quarter. Last quarter management committed to a sequential step-up in PCS as the product hold cleared, and Q4 organic of -1.1% suggested the recovery was tracking. This quarter PCS reported -8.1% organic with a 500bps segment margin decline, and management's language — "PCS being more of a standalone segment really in the future, we have the opportunity to do more of a strategic assessment of the portfolio" — is a meaningful escalation. This is the first call where divestiture optionality has been telegraphed for a segment that contributes ~14% of revenue.

China rotated from "embedded decline with green shoots" to a more textured stabilization read. The framing has progressed from Q2's "not counting on China," to Q3's "intact medium-term goals even if China flat," to Q4's "prudent approach with embedded decline," to this quarter's "more challenged year, but I think we're starting to get more stabilization." The directional improvement is genuine; the magnitude is small and conditional on tender pipeline execution.

PDX picked up a Q1 supplier quality issue worth roughly five cents of EPS — a tangible operational misstep in the segment that has carried the growth narrative for four quarters. The issue itself contradicts the operational excellence framing that has anchored PDX commentary since Flyrcado's reset.

Recurring themes management leaned on this quarter:

Inflation management and cost mitigation (memory chips, freight, commodities totaling $250M)New product innovation pipeline transitioning from regulatory approval to commercial revenue (photon counting CT, advanced MR, AI-enabled products)Flercado radiopharmaceutical ramp-up with dose acceleration but supply/workflow constraintsOrganizational restructuring (combining imaging and AVS into Advanced Imaging Solutions) to drive faster innovation and commercial executionChina market stabilization with cautious outlook but green shoots emergingServices and recurring revenue as growth and margin driversIntelliRad acquisition integration supporting cloud-first enterprise imaging ecosystem

Risks management surfaced:

Persistent elevation of memory chip costs and freight/oil price volatility through full year 2026PCS backlog conversion delays and margin pressure from monitoring equipment concentration in second halfGeneric contrast media entrants into pharmaceutical diagnostics market (though no impact observed Q1)China market continued pressure requiring execution on stabilization initiativesTariff policy uncertainty with no material benefit anticipated from recent policy changes; refunds from prior year tariffs unresolved

Answers to last quarter's watch list

Whether the FY2026 EBIT margin guide gets raised mid-year as Heartbeat productivity compounds. The opposite happened — FY2026 adjusted EBIT margin guide was cut by 40bps across the range, with YoY expansion now 10-40bps versus the prior 50-80bps. The Heartbeat productivity story is not visibly broken, but it is no longer sufficient to offset $250M of incremental inflation.

Resolved negatively

Q1 FY2026 organic landing at the high end of 2-3% or above. Came in at 2.9% — at the high end of the guide but below the 3%+ threshold that would have signaled upside to the FY 3-4% range. The watch is technically met but does not deliver the upside read it was set up to test. Status: Resolved in-line

Flyrcado FY2025 actual dollar contribution and FY2026 trajectory. Not disclosed in the press release; the company referenced dose acceleration (390 doses week ended April 17, ~80% increase since late January) and supply/workflow execution but did not give a specific FY2025 actual or FY2026 dollar trajectory. The half-billion-by-2028 path is reaffirmed qualitatively but unverifiable in dollar terms from this print.

Not resolved

Organic orders growth re-accelerating off the Q4 2.0% trough. Q1 organic orders growth came in at 1.1% — decelerating further, not re-accelerating. Book-to-bill held at 1.07x and management ties the softness to the 10.3% prior-year comp, but the 2027 acceleration narrative now lacks an orders-side confirmation.

Resolved negatively

2026 net tariff EPS impact quantified. Q1 alone carried ~$0.16 of tariff EPS impact. Management stated FY tariff impact in 2026 will be lower than 2025 and assumes no material benefit from recent policy changes; prior-year refund disputes remain unresolved. The directional commitment holds but a full-year cents-per-share figure was not provided.

Continue monitoring

China commentary. Tone modestly upgraded from "embedded decline" to "more stabilization…green shoots" while still expecting China sales down YoY in 2026. Directional improvement, no inflection.

Continue monitoring

What to watch into next quarter

Whether Q2 FY2026 organic lands at the high end of the 3-4% guide or above. With Q1 at 2.9%, the FY 3-4% guide already requires back-half acceleration; a Q2 print below 3.5% would force a hard question on whether the FY revenue guide should also be cut.

Whether the FY2026 EPS guide gets cut again or stabilizes. Management mitigated $250M of gross inflation to ~$0.15 of net EPS impact with ~$0.23 of offsets weighted to H2; if memory chip and freight costs stay elevated and the H2 mitigation actions underperform, the $4.80-$5.00 range is at risk of a further trim, particularly given Q2 is already guided to YoY EPS decline.

PCS strategic assessment under the new three-segment structure. Management's "more standalone segment…strategic assessment of the portfolio" language is the most explicit divestiture signal in eight quarters of GEHC coverage; the new AIS/PDx/PCS structure makes carve-out optionality cleaner. Any concrete framing of carve-out, sale, or restructuring would be a material event.

Organic orders growth rebound to mid-single-digit by Q2 or Q3. Last quarter's 2.0% and this quarter's 1.1% are now a two-quarter deceleration; the 2027 imaging NPI acceleration thesis requires orders to inflect well ahead of revenue.

Imaging NPI revenue timing and Photonova Spectra funnel conversion. The H1 2027 framing is the third push-out in three quarters; another slippage would meaningfully compress the 2027 acceleration window. The $100M+ photon counting funnel and 4-6 month assessment / 5-8 month install timing are the leading indicators to track.

PDX delivery rate and any further supplier quality disclosures. The $0.05 Q1 hit is small, but the segment's growth premium depends on operational excellence; a second incident in Q2 would change the narrative.

Sources

GE HealthCare Q1 FY2026 earnings press release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1932393/000193239326000030/release1q26earnings.htm
GE HealthCare Q1 FY2026 earnings call — prepared remarks and Q&A.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.